Related Experiment Video
Updated: Jul 14, 2026
10:37
Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic
E J Topol1, D J Moliterno, H C Herrmann
1Department of Cardiology, Cleveland Clinic Foundation, OH 44195, USA. topole@ccf.org
The New England Journal of Medicine
|June 23, 2001
Summary
Abciximab demonstrated superiority over tirofiban in preventing major ischemic events following percutaneous coronary revascularization. This study found tirofiban offered less protection, highlighting abciximab
Area of Science:
- Cardiology
- Pharmacology
- Interventional Cardiology
Background:
- Platelet glycoprotein IIb/IIIa inhibitors significantly reduce risks after percutaneous coronary revascularization.
- Assessing comparative safety and efficacy of tirofiban versus abciximab is crucial.
Purpose of the Study:
- To evaluate if tirofiban is non-inferior to abciximab in preventing major adverse cardiac events.
- To compare the safety and efficacy profiles of tirofiban and abciximab.
Main Methods:
- A double-blind, double-dummy, randomized trial involving 4709 patients across 18 countries.
- Patients received either tirofiban or abciximab before percutaneous coronary revascularization with stenting.
- The primary endpoint was a composite of death, myocardial infarction, or urgent target-vessel revascularization at 30 days.
Main Results:
- Abciximab was superior to tirofiban, with a lower incidence of the primary endpoint (6.0% vs 7.6%; P=0.038).
- Abciximab showed significant superiority in reducing myocardial infarction (5.4% vs 6.9%).
- Tirofiban was associated with fewer minor bleeding episodes and lower rates of thrombocytopenia, with no significant difference in major bleeding.
Conclusions:
- The study failed to demonstrate the non-inferiority of tirofiban compared to abciximab.
- Abciximab provided better protection against major ischemic events in patients undergoing percutaneous coronary revascularization.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:27Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
01:27Peripheral Artery Disease III: Interprofessional Care
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...